Key terms
About CVAC
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CVAC news
Today
7:51am ET
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
Yesterday
5:30pm ET
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
Yesterday
5:29pm ET
CureVac Launches Study for H5N1 Influenza Vaccine
Yesterday
5:28pm ET
CureVac Names New Chief Business Officer
Yesterday
4:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
Yesterday
7:31am ET
CureVac names Thaminda Ramanayake chief business officer
Yesterday
7:29am ET
CureVac, GSK announce start of Phase 1 part of investigational H5N1 trial
Yesterday
7:29am ET
CureVac announces start of Phase 1/2 study in avian influenza
Yesterday
7:28am ET
CureVac appoints Thaminda Ramanayake as CBO
Apr 18
12:29am ET
CureVac (CVAC) Gets a Buy from Leerink Partners
Apr 16
5:27pm ET
CureVac Partners with MD Anderson on Cancer Vaccines
Apr 16
7:25am ET
CureVac, MD Anderson enter collaboration for cancer vaccines
Apr 08
3:27am ET
Leerink Partners Keeps Their Buy Rating on CureVac (CVAC)
Apr 04
4:57pm ET
CureVac’s Influenza Vaccine Shows Strong Phase 2 Results
Apr 04
7:23am ET
CureVac announces Phase 2 interim data from influenza vaccine program
No recent press releases are available for CVAC
CVAC Financials
Key terms
Ad Feedback
CVAC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CVAC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range